Chronic myelogenous leukemia: mechanisms underlying disease progression

被引:116
作者
Shet, AS
Jahagirdar, BN
Verfaillie, CM
机构
[1] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Div Hematol Oncol & Trasplantat, Dept Med, Minneapolis, MN 55455 USA
关键词
chronic myelogenous leukemia; BCR-ABL; blast crisis; disease progression; mechanisms;
D O I
10.1038/sj.leu.2402577
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic myelogenous leukemia (CML), characterized by the BCR-ABL gene rearrangement, has been extensively studied. Significant progress has been made in the area of BCR-ABL-mediated intracellular signaling, which has led to a better understanding of BCR-ABL-mediated clinical features in chronic phase CML. Disease progression and blast crisis CML is associated with characteristic non-random cytogenetic and molecular events. These can be viewed as increased oncogenic activity or loss of tumor suppressor activity. However, what causes transformation and disease progression to blast crisis is only poorly understood. This is in part due to the lack of a good in vivo model of chronic phase CML even though animal models developed over the last few years have started to provide insights into blast crisis development. Thus, additional in vitro and in vivo studies will be needed to provide a complete understanding of the contribution of BCR-ABL and other genes to disease progression and to improve therapeutic approaches for blast crisis CIVIL.
引用
收藏
页码:1402 / 1411
页数:10
相关论文
共 179 条
[21]   p62(dok): A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells [J].
Carpino, N ;
Wisniewski, D ;
Strife, A ;
Marshak, D ;
Kobayashi, R ;
Stillman, B ;
Clarkson, B .
CELL, 1997, 88 (02) :197-204
[22]   c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells [J].
Ceballos, E ;
Delgado, MD ;
Gutierrez, P ;
Richard, C ;
Müller, D ;
Eilers, M ;
Ehinger, M ;
Gullberg, U ;
León, J .
ONCOGENE, 2000, 19 (18) :2194-2204
[23]   The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells [J].
Cortez, D ;
Reuther, G ;
Pendergast, AM .
ONCOGENE, 1997, 15 (19) :2333-2342
[24]  
Cortez D, 1996, ONCOGENE, V13, P2589
[25]  
CORTEZ D, 1995, MOL CELL BIOL, V15, P5531
[26]   BCR-ABL - AN ANTI-APOPTOSIS GENE IN CHRONIC MYELOGENOUS LEUKEMIA [J].
COTTER, TG .
LEUKEMIA & LYMPHOMA, 1995, 18 (3-4) :231-236
[27]   Identification of several genes differentially expressed during progression of chronic myelogenous leukemia [J].
Dahéron, L ;
Salmeron, S ;
Patri, S ;
Brizard, A ;
Guilhot, F ;
Chomel, JC ;
Kitzis, A .
LEUKEMIA, 1998, 12 (03) :326-332
[28]   INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].
DALEY, GQ ;
VANETTEN, RA ;
BALTIMORE, D .
SCIENCE, 1990, 247 (4944) :824-830
[29]  
de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231
[30]   BCR-ABL down-regulates the DNA repair protein DNA-PKcs [J].
Deutsch, E ;
Dugray, A ;
AbdulKarim, B ;
Marangoni, E ;
Maggiorella, L ;
Vaganay, S ;
M'Kacher, R ;
Rasy, SD ;
Eschwege, F ;
Vainchenker, W ;
Turhan, AG ;
Bourhis, J .
BLOOD, 2001, 97 (07) :2084-2090